The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311 C90)

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 9, 1997, Pages 398-

  Seaber, E ^a   On, N ^a   Dixon, R M ^a   Gibbnes, M ^a   Leavens, W J ^a   Liptrot, J ^a   Chittick, G ^a   Posner, J ^a   Rolan, P E ^a   Peck, R W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NOTE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0030804445     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (0)